A clinical and molecular analysis of mosaicism — the presence of two or more genetically distinct cell populations in a single individual. Covers somatic and germline mosaicism, diagnostic strategies, and the profound implications for recurrence risk counseling in families with apparent de novo conditions.
Tags: Neurogenetics · Advanced
Mosaicism arises when a postzygotic mutational event — occurring after fertilization — creates a subpopulation of cells carrying a genetic alteration distinct from the original zygote. The earlier the mutation occurs during development, the larger the proportion of affected cells and the more widespread its distribution across tissues. Mutations arising in the first few cell divisions can affect all three germ layers; those occurring later are more restricted. The mutation can be a chromosomal non-disjunction, structural rearrangement, single nucleotide variant, copy number variant, or epigenetic change.
Key Points
Chromosomal mosaicism results from mitotic errors that generate cell lines with abnormal chromosome number or structure alongside a normal diploid line. Phenotypic consequences depend on which chromosome is involved, the proportion of abnormal cells, and the tissue distribution at critical periods of organogenesis. Mosaicism typically produces a milder phenotype than the constitutional aneuploidy, but phenotypic prediction from a karyotype alone is unreliable because blood karyotype may not reflect brain or gonadal cell populations.
Key Points
Somatic mosaicism is increasingly recognized as a cause of conditions previously thought to be purely de novo or even sporadic. Brain somatic mosaicism — mutations arising in neural progenitor cells during cortical neurogenesis — is now understood to be a major cause of focal cortical dysplasia, hemimegalencephaly, and certain epilepsy syndromes. Because the mutation is present only in a fraction of brain cells (and often absent in blood), standard germline sequencing misses these variants, requiring high-depth sequencing of affected tissue.
Key Points
Germline (gonadal) mosaicism occurs when a postzygotic mutation is confined to — or substantially enriched in — germ cells, leaving somatic cells largely unaffected. The clinically normal parent can be an unsuspected carrier whose germ cells harbor a pathogenic variant, allowing transmission to multiple children. This is the critical concept that explains why a second affected child can be born to apparently unaffected parents of a child with a supposedly de novo condition. Germline mosaicism has been documented for many autosomal dominant disorders including osteogenesis imperfecta, DMD, Rett syndrome, and rasopathies.
Key Points
Detecting mosaicism requires understanding the sensitivity limits of each diagnostic platform and selecting the appropriate tissue source. Standard clinical sequencing (NGS panels, exome, genome) at typical depths (50–100×) can detect variants present in >10–15% of cells; lower VAF requires specialized approaches. Tissue selection is paramount — testing blood may miss variants confined to brain or skin, and testing buccal cells may miss blood-specific mosaicism.
Key Points
1. A child presents with a unilateral port-wine stain in the V1 dermatome, ipsilateral leptomeningeal angioma on MRI, and seizures. Blood-based exome sequencing is negative. The most likely genetic etiology is:
Sturge-Weber syndrome is caused by a somatic activating variant in GNAQ (p.R183Q) that arises in cephalic neural crest cells during early embryogenesis. Because the variant is confined to affected vascular and neural tissues (VAF typically 1-15%), it is absent from blood in most patients and will not be detected by standard blood-based sequencing. Deep sequencing of affected tissue (brain or skin biopsy from the port-wine stain) is needed for molecular confirmation.
2. An apparently de novo pathogenic variant in MECP2 is confirmed in a girl with Rett syndrome. Her parents test negative on standard clinical sequencing of blood. The genetic counselor should advise that:
Even when a variant appears de novo (absent in parental blood), germline mosaicism in one parent cannot be excluded. For MECP2/Rett syndrome, the empirical recurrence risk due to germline mosaicism is approximately 0.5-1%. This is clinically significant enough to warrant offering prenatal diagnosis (CVS or amniocentesis) or preimplantation genetic testing (PGT-M) in subsequent pregnancies. Counseling families that recurrence risk is 'zero' based solely on negative parental blood testing is inaccurate.
3. A patient with mosaic Down syndrome (47,+21[8]/46,XX[22]) has milder cognitive impairment than expected for constitutional trisomy 21. A genetic counselor is asked whether the blood karyotype predicts her neurological outcome. The most accurate response is:
The proportion of abnormal cells in blood karyotype does not reliably reflect the proportion of trisomic cells in the brain or other tissues. During embryogenesis, random distribution of the two cell lines to different tissues means that the brain may have a higher or lower percentage of trisomic cells than blood. While mosaic Down syndrome generally produces milder features than constitutional trisomy 21, the correlation between blood mosaicism level and cognitive outcome is poor, making prognostic predictions from the karyotype unreliable.
4. A child with drug-resistant focal epilepsy undergoes surgical resection. Deep sequencing of the resected cortex reveals a PIK3CA somatic variant at 8% variant allele fraction. This finding is clinically significant because:
Somatic activating variants in PI3K-AKT-mTOR pathway genes (PIK3CA, MTOR, AKT3) in neural progenitor cells are a major cause of focal cortical dysplasia (FCD type II) and hemimegalencephaly. The variant allele fraction in resected tissue is typically 1-20%, reflecting the proportion of affected neurons. These variants cause constitutive pathway activation leading to abnormal cortical development and epileptogenesis. Detection requires deep sequencing of brain tissue with somatic variant calling — the variant would be undetectable in blood.
5. A genetics laboratory reports that standard exome sequencing (80× mean depth) reliably detects mosaic variants down to approximately 10–15% VAF. A clinician suspects lower-level somatic mosaicism in a patient with focal cortical dysplasia. Which testing strategy would most improve detection sensitivity?
Ultra-deep targeted sequencing at 1000x or greater depth, combined with somatic variant calling algorithms, can detect mosaic variants at VAFs as low as 0.5-1%. Standard exome sequencing at 80x cannot reliably detect variants below 10-15% VAF. Sanger sequencing is even less sensitive (~20-25% VAF threshold). Chromosomal microarray detects copy number changes, not single-nucleotide variants. For suspected low-level mosaicism, increasing sequencing depth on a targeted region is the most effective strategy.